
ReproNovo has dosed the first participant in its phase 2 NORDIC study evaluating RPN-002, an investigational therapy designed to improve …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

